Advisors: Explain Medicare’s $50 GLP-1 Bridge Program

Medicare will begin covering three FDA-approved GLP-1 weight-loss drugs-Wegovy, Zepbound and Foundayo-on July 1 under an 18-month Bridge program that runs through Dec. 31, 2027. The program applies to eligible Medicare beneficiaries and is designed as a temporary trial while regulators consider broader coverage policies.

The program covers adults with a body-mass index of 30 or higher, or a BMI of 27 or more plus a weight-related comorbidity. Beneficiaries must not have filled a GLP-1 prescription under their Part D plan in 2026. Physicians must certify medical need before Medicare will approve coverage.

Enrollees who meet the clinical criteria will pay a $50 monthly copay. That copay does not count toward the Part D deductible or the Part D out-of-pocket spending cap. Brand-name GLP-1 treatments cost roughly $700 to $800 per month in the U.S. without insurance coverage.

The Kaiser Family Foundation estimates about 4 million Medicare beneficiaries could qualify for the Bridge program. A national poll found 11% of U.S. adults used injectable GLP-1s for weight loss in 2026, up from 3% in 2024.

Dr. Dennis Weaver, chief clinical officer at Pearl Health, urged beneficiaries to consider how long-term GLP-1 use will fit into their Part D plans and said, “When managing obesity, which is a chronic condition, using a GLP-1, downstream effects that lead to improved health potentially save thousands of dollars of health care expenses in the long run.”

Analyses have found GLP-1 drugs did not meet common cost-effectiveness benchmarks at current U.S. prices. A 2025 estimate from Fidelity put expected health-related retirement costs at more than $170,000 per retiree. Data from AARP show the cost of long-term services and supports rose about 50% from 2019 to 2024.

Dr. Warris Bokhari, CEO and co-founder of Claimable, noted manufacturers will need to work with the Centers for Medicare & Medicaid Services if access is to continue after the trial and warned that prior authorization models that use AI-assisted reviews could complicate approvals. He added that a predictable $50 copay may reduce the need for beneficiaries to pursue appeals.

Advisors and clinicians recommend that beneficiaries who may qualify review clinical eligibility, consult their physicians about medical necessity and assess how ongoing GLP-1 therapy would interact with their Part D plan and retirement health-care budget.